Therapeutics , Targets , and Chemical Biology Oncogenic Kras Promotes Chemotherapy-Induced Growth Factor Shedding via ADAM 17

@inproceedings{Schaeybroeck2011TherapeuticsT,
  title={Therapeutics , Targets , and Chemical Biology Oncogenic Kras Promotes Chemotherapy-Induced Growth Factor Shedding via ADAM 17},
  author={Sandra Van Schaeybroeck and Joan N Kyula and Audrey Fenton and Catherine S. Fenning and Takehiko Sasazuki and Senji Shirasawa and Daniel Broderick Longley and Patrick Gerard Johnston},
  year={2011}
}
Oncogenic mutations in Kras occur in 40% to 45% of patients with advanced colorectal cancer (CRC). We have previously shown that chemotherapy acutely activates ADAM17, resulting in growth factor shedding, growth factor receptor activation, and drug resistance in CRC tumors. In this study, we examined the role of mutant Kras in regulating growth factor… CONTINUE READING